Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation Trial

Completed

Conditions: Paroxysmal Atrial Fibrillation
Circulatory System
Atrial fibrillation

Registration Number: ISRCTN88528808

Lead Sponsor: German Atrial Fibrillation Network

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 422

Inclusion Criteria

1. Documented paroxysmal atrial fibrillation: electrocardiogram (ECG) documentation of atrial fibrillation at least
in one ECG recorded during the last 2 months prior to randomization plus additional ECG recording of sinus rhythm at least 12 hours after the above mentioned ECG documentation
2. Age =18
3. Patient informed orally and in writing
4. Written informed consent of the patient

Exclusion Criteria

1. Strong clinical evidence for therapy with AT II/ACE inhibitors within the last month
2. Therapy with antiarrhythmic agents of class I or class III within the last month, therapy with amiodaron within the last 3 months
3. DC cardioversion within the last 3 months
4. Symptomatic bradycardia
5. Implanted pacemaker or implanted cardioverter/defibrillator with any antitachycardiac algorithm in use
6. Cardiac surgery or cardiac catheter ablation within the last 3 months
7. Typical angina pectoris symptoms at rest or during exercise
8. Known coronary artery disease with indication for intervention
9. Valvular disease >II degree
10. Left ventricular ejection fraction <40%
11. Diastolic blood pressure >110 mmHg at rest
12. Symptomatic arterial hypotension
13. Known renal artery stenosis
14. Serum creatinine >1.8 mval/l

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)

Secondary Outcome Measures

Name	Time	Method
1. Time to first occurrence of a documented relapse of atrial fibrillation<br>2. Time to first occurrence of a symptomatic documented episode of AF<br>3. Time to persistent atrial fibrillation<br>4. Time to prescription of the recovery-medication<br>5. Number of hospitalizations for cardiovascular reasons (-> Endpoint review)<br>6. Number of intermediate medical visits for cardiovascular reasons (-> Endpoint review) without hospitalization<br>7. Number of cerebrovascular events<br>8. Quality of life